- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This paper offers a brief analysis of these two challenges in light of current policies and practices, along with recommendati ons for overcoming them to ensure the implementati on of a drug treatment system that can result in improved health and human rights outcomes for people who use drugs and people dependant on drugs.
Antiretroviral treatment (ART) optimization is a key pillar in the AIDS Free agenda to reach the goal of ensuring 95% of all infants and children have access to lifesaving treatment.
This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal ARV medicines and dosage forms become available.
Keywords: HIV, ARV, paediatric, treatment, children
Every child and adolescent living with HIV should have access to antiretroviral therapy (ART). The AIDS Free component of the framework has the specific goal of ensuring 95% of all children and adolescents living with HIV have access to lifelong ART by the end of 2018. These efforts will need to be sustained until 2020, when it is estimated that treating 95% of all children and adolescents living with HIV will require providing ART to 1.4 million children (aged 0-14). and 1 million adolescents (aged 15-19).
Update on antiretroviral regimens for treating and preventing HIV infection: Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment.
Update on early infant diagnosis of HIV: In 2016, WHO recommended that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result.
Keywords: HIV, ART, diagnosis, treatment
Twenty years of evidence demonstrates that HIV treatment is highly effective in reducing the transmission of HIV. People living with HIV on antiretroviral therapy who have an undetectable level of HIV in their blood have a negligible risk of transmitting HIV sexually.
This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
This strategic framework provides a road map to scale-up PPTCT services in the most efficient manner, where value for money is achieved with the promise that no infected mother will be missed and no child will be born with HIV, where every HIV exposed infant will receive the much needed HIV test at 6 weeks of age, and linked to treatment where required.
This report is an account of the Region’s progress in developing and implementing NAPs. The report provides a platform to track what is going well, and to identify areas where extra efforts are needed. In the report, the regional roadmap for strengthening national AMR prevention and containment programmes is analysed with a specific methodology. The results gathered have been compiled to contribute to country profiles which make the report more useful.
Keywords: AMR, situation analysis, surveillance, prevention
Find HIV data on PMTCT, ANC, pregnant women, ART in Nepal.
The WHO/HIVResNet Laboratory Operational Framework describes how WHO HIVResNet laboratories function to support national, regional, and global HIV drug resistance (HIVDR) surveillance by providing accurate genotyping results in a standardized format according to WHO specifications.
Keywords: HIV, laboratory services, drug resistance